ArticleAntimicrobial agents and chemotherapy2022
Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Isolation and genomic analysis of otomycosis pathogens, and genomics-informed antimicrobial peptide design with potential therapeutic applications.BMC microbiology · 2026Article
- Iron starvation confers azole tolerance inmBio · 2026Article
- A deep dive into the diversity of theFrontiers in public health · 2026Article
- When Should Clinical Mycology Laboratories Perform Antifungal Susceptibility Testing? Revisiting Practice Through the Lens of Intrinsic Resistance.Mycopathologia · 2025Review
- Isavuconazole-Amphotericin B and Isavuconazole-Caspofungin In Vitro Synergic Activity Against Invasive Pulmonary Aspergillosis Molds Isolates.Antibiotics (Basel, Switzerland) · 2025Article
- Genotypic and Phenotypic Investigation of Clinical Aspergillus isolates from Iran Indicates Nosocomial Transmission Events of Aspergillus flavus.Mycopathologia · 2025Article
- The impact of respiratory tract mimicking media on antifungal susceptibility testing.Antimicrobial agents and chemotherapy · 2025Article
- Insights into Persian Gulf Beach Sand Mycobiomes: Promises and Challenges in Fungal Diversity.Journal of fungi (Basel, Switzerland) · 2025Article
- Exploring Factors Driving the Uneven Distribution ofMicroorganisms · 2025Article
- Review
- DecipheringMicrobiology spectrum · 2025Article
- Article
- Article
- Review
- Identification ofFrontiers in veterinary science · 2025Article
- Isavuconazole and Amphotericin B Synergic Antifungal Activity: In Vitro Evaluation on Pulmonary Aspergillosis Molds Isolates.Antibiotics (Basel, Switzerland) · 2024Article
- Brain glucose induces tolerance of Cryptococcus neoformans to amphotericin B during meningitis.Nature microbiology · 2024Article
- Accelerating the understanding ofCurrent research in microbial sciences · 2024Review
- Lipid-Based Nanotechnology: Liposome.Pharmaceutics · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Aspergillus terreus is an opportunistic causative agent of invasive aspergillosis and, in most cases, it is refractory to amphotericin B (AMB) therapy. Notably, AMB-susceptible Aspergillus terreus
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.